Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T-Mobile Us Inc (TMUS) vs 22nd Century Group Inc (XXII) Price & Performance

T-Mobile Us IncTrade
22nd Century Group IncTrade

Price performance (Past 24H)

Key statistics

T-Mobile Us Inc vs 22nd Century Group Inc — how do they compare? T-Mobile Us Inc trades at $148.45 (market cap $183.76B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: T-Mobile Us Inc is far larger — about 295590.9× 22nd Century Group Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Mobile Us Inc for 84 Days and 22nd Century Group Inc for 32 Days on average.

TMUSXXII
Market Cap
$183.76B$621.67K
Volume
4,294,65045,625
Sector
MediaConsumer Staples
52-Week High
$230.06$483.00
52-Week Low
$161.73$0.80
Typical Hold Time
84 Days32 Days
Enterprise Value
$300.37B-$3.69M
Dividend Yield
2.73%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T-Mobile Us Inc

T-Mobile (TMUS) is trading at $149.79, down 10.64% in the last session. The stock shows strong fundamentals with revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability (net margin 11.45%). Recent technical indicators are mixed with a bearish moving average signal but neutral oscillators. The company announced a 15% dividend increase and is advancing AI-powered 5G network capabilities. Analyst consensus remains strongly bullish with 79.6% buy ratings and a $231.10 price target.

TMUS presents a compelling growth story with solid financials and strategic initiatives, though elevated debt levels and competitive pressures pose risks. The current price decline may offer an entry point given the significant upside to analyst targets, supported by consistent earnings beats and dividend growth.

22nd Century Group Inc

22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.

While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TMUS
53% Buy47% Sell
Avg holding period · 84 Days
XXII
100% Buy0% Sell
Avg holding period · 32 Days

Top news

Latest headlines on both assets

About T-Mobile Us Inc

Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.

Read more on TMUS →

About 22nd Century Group Inc

22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.

Read more on XXII →